The key takeaways for this program are:
- Understanding the Prometheus decision and what the Supreme Court did and did not say;
- Understanding the question at issue in Myriad and how it is similar—and different—from that decided in Prometheus;
- Learning possible patent claim strategies to protect personalized medicine methods and biotechnology inventions under the new paradigm;
- Reviewing the U.S. Patent Office Guidance to Examiners, issued shortly after the Supreme Court decided Prometheus; and
- Discussing Options for strengthening already granted patents.
People
Related Insights
10 October 2024
Viewpoints
Proposed Rule Targeting Connected Vehicles Will Impose Major New Supply Chain Compliance Requirements on Automotive Companies that Source from Russia or China
On September 26, 2024, the Department of Commerce’s Bureau of Industry and Security (BIS) published a Notice of Proposed Rulemaking that, if finalized, would prohibit the sale or import of certain automotive hardware and software, as well as “connected vehicles” incorporating this technology, from or linked to the People’s Republic of China or Russia.
11 October 2024
Events
Managing Risk and Driving Resilience | Cybersecurity Summit 2024
On Friday, October 11, Foley Partner Jen Urban will speak on the panel titled, “Managing Risk and Driving Resilience.”
10 October 2024
Manufacturing Industry Advisor
Stellantis Files String of Lawsuits Against UAW Claiming Strike Threats Are Bad Faith
On October 7, 2024, in a coordinated attack, Chrysler owner Stellantis filed a string of lawsuits across multiple jurisdictions against the United Auto Workers Union (“UAW”) and numerous local chapters regarding the UAW’s threats to strike if Stellantis does not move forward with planned investments in its U.S. operations.